Attached files
| file | filename |
|---|---|
| EX-10.15 - EX-10.15 - Longboard Pharmaceuticals, Inc. | d16883dex1015.htm |
| EX-10.14 - EX-10.14 - Longboard Pharmaceuticals, Inc. | d16883dex1014.htm |
| EX-10.13 - EX-10.13 - Longboard Pharmaceuticals, Inc. | d16883dex1013.htm |
| EX-10.8 - EX-10.8 - Longboard Pharmaceuticals, Inc. | d16883dex108.htm |
| EX-10.2 - EX-10.2 - Longboard Pharmaceuticals, Inc. | d16883dex102.htm |
| EX-10.1 - EX-10.1 - Longboard Pharmaceuticals, Inc. | d16883dex101.htm |
| EX-4.2 - EX-4.2 - Longboard Pharmaceuticals, Inc. | d16883dex42.htm |
| EX-3.4 - EX-3.4 - Longboard Pharmaceuticals, Inc. | d16883dex34.htm |
| EX-3.3 - EX-3.3 - Longboard Pharmaceuticals, Inc. | d16883dex33.htm |
| EX-3.2 - EX-3.2 - Longboard Pharmaceuticals, Inc. | d16883dex32.htm |
| S-1 - S-1 - Longboard Pharmaceuticals, Inc. | d16883ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Longboard Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
San Diego, California
February 19, 2021